Emerging Markets Earnings Roundup: Bayer (Part 8)
This article was originally published in PharmAsia News
Bayer saw 40% of its revenues come from emerging markets in the fourth quarter of 2013. The health care business unit lagged in Asia for the year, but the company expects rapid growth in China through acquisitions and other expansion plans.
You may also be interested in...
Few biotechs are acquired by their partners -- only about a half dozen in each of the last two years, making the Bayer acquisition of Algeta an exception to the rule. Like other recent billion-dollar partner acquisitions, expectations for subsequent performance seem high.
The German conglomerate highlights sales of its five new medicines that have gotten off to good starts in the marketplace and has identified another five early stage cardiology and oncology products to push through its pipeline.
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.